ClinicalTrials.gg
CompletedNCT05817240Updated Dec 15, 2023

A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects

A Phase 1 interventional study of taladegib and nintedanib in Idiopathic Pulmonary Fibrosis, sponsored by Endeavor Biomedicines, Inc.. Completed at 1 site in Australia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-15.

Sponsored by Endeavor Biomedicines, Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jun 2023, 3 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis — 1 open to participants now, 1 under way, none of them phase 3. nintedanib · Idiopathic Pulmonary Fibrosis.

Enrollment
14th of 16
21 · median 49
Started
2023
with 1 other
Phase 1
6 of 16
none open now
Registered
14th of 16
by date
Lead sponsor
1 of 16
Endeavor Biomedicines, Inc.

Among the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, this one is the 14th largest by enrollment, is one of 2 that started in 2023, is one of 6 in phase 1, and was the 14th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

1 of the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis is open now. Recruiting first, the newest first:

About nintedanib

nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about the potential effect of ENV-101 (taladegib) on the pharmacokinetics of nintedanib (an approved treatment for idiopathic pulmonary fibrosis) when the two compounds are dosed together in healthy subjects. Participants in this study will receive ENV-101 and/or nintedanib on various days throughout a 10-day period during which they will reside at the clinical trial site.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • smoothened
  • hedgehog
  • pulmonary fibrosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) ≥18 and ≤32 kg/m\^2
  • Body weight ≤120kg
  • Subjects must be willing to be sequestered for 10 consecutive days.

Exclusion criteria

Exclusion Criteria:

  • Chronic or current use of any prescription medications or acute use within the preceding 30 days or 5 half-lives, whichever is longer, with the exception of , prior to study start
  • Subject has an active infection of or C, or (HIV) at study start
  • Subject has a history of of any type, other than in situ cervical cancer or surgically excised non-melanomatous skin cancers, within 5 years before study start
  • Participation in a clinical research trial that included the receipt of an agent or any experimental procedure within 30 days or 5 half-lives, whichever is longer, prior to the screening visit, or planned participation in any such trial at time of study start
  • Subject has a pulse \<45 or >100 bpm; systolic blood pressure >160 mmHg, or diastolic blood pressure >95 mmHg at study start
  • Subject has pacemaker; is not in sinus rhythm; has a interval (QTc; using Fridericia's [QTcF] formula) of >450 ms (for males) and >470 ms (for females) during the Screening Period; or has a left bundle branch block or bifascicular block.
  • Females and males of who are sexually active and unwilling to use birth control for the duration of the study and for 90 days after their final study dose
  • Females that are pregnant or lactating
  • Females and males that are unwilling to refrain from blood or blood product donation for the duration of the study and for 30 days after their final study dose
  • Males who are unwilling to refrain from sperm donation for the duration of the study and for 90 days after their final study dose
  • Females who are unwilling to refrain from egg donation for the duration of the study and for 90 days after their final study dose
  • Subjects with a history of a severe allergic reaction or anaphylactic reaction or known to any component of ENV-101 (taladegib) or nintedanib
  • Subjects who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study investigative site or the study Sponsor
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Experimental

    Drug: taladegib · Drug: nintedanib

Interventions

  • 100 mg per tablet, dosed once daily

    Also known as: ENV-101

  • 100 mg per capsule, dosed once daily

06

What researchers measure

Primary outcomes

  1. Nintedanib maximum blood concentration (Cmax) after administration alone and after coadministration with ENV-101 (taladegib)

    Time frame: Day 1 and Day 7

  2. Time of nintedanib maximum blood concentration (Tmax) after coadministration alone and after coadministration with ENV-101 (taladegib)

    Time frame: Day 1 and Day 7

  3. Nintedanib absorption to time t (AUC0-t) after administration alone and after coadministration with ENV-101 (taladegib)

    AUC represents "area under the concentration-time curve" and measures the amount of drug that is present in the blood from the time of administration to a given time t

    Time frame: Day 1 and Day 7

  4. Nintedanib total absorption (AUC0-inf) after administration alone and after coadministration with ENV-101 (taladegib)

    Time frame: Day 1 and Day 7

  5. Nintedanib half-life in the blood (T1/2) after administration alone and after coadministration with ENV-101 (taladegib)

    Time frame: Day 1 and Day 7

07

Study locations

1 site
  • Research Site
    Adelaide, South Australia 5000, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Jun 2023, 1 month.

Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 1 month is below that.

Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2023
First posted
Apr 18, 2023
StartActual
May 3, 2023
Primary completionActual
Jun 11, 2023
CompletionActual
Jun 21, 2023
Last update
Dec 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05817240
Lead sponsor
Endeavor Biomedicines, Inc.
Responsible party
Sponsor
First posted
Apr 18, 2023
Start date
May 3, 2023
Primary completion
Jun 11, 2023
Completion
Jun 21, 2023
Last update
Dec 15, 2023

Study contacts

Paul Frohna, M.D., Ph.D.
study director · Endeavor Biomedicines

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: LY2940680 · Nintedanib

Start the discussion